10/25/2007

Pharmasset's chronic hepatitis C drug candidate R7128 has obtained fast-track status from the FDA. The company is currently testing the effectiveness of the drug in combination with Pegasys and Copegus in chronic hepatitis C patients who have stopped responding to other treatments.

Full Story:
Forbes

Related Summaries